Compound profile
Kisspeptin-54
Limited human dataAlso known as: Metastin · KP-54
A naturally occurring neuropeptide that is the master regulator of the reproductive hormone axis, now in early clinical development as a fertility and psychosexual therapeutic. Distinct from the melanocortin-based sexual-health peptides: it works directly on the reproductive hormone cascade.
Overview
Kisspeptin-54 is a naturally occurring peptide that sits at the top of the hormonal cascade controlling human reproduction. It is one of several peptide products of a single gene, and its job is to talk directly to the neurons in the brain that control the release of reproductive hormones, making it arguably the master switch of the reproductive system rather than a downstream player.
The peptide's history starts somewhere unexpected. In 1996, researchers screening for genes that suppress cancer metastasis in melanoma cells at Hershey, Pennsylvania identified a new gene and named it KISS1, a reference to Hershey's chocolate kisses. Only later did researchers connect the KISS1 gene product to reproductive biology, when its receptor, GPR54, was found to be essential for puberty and fertility. The 54-amino-acid peptide cleaved from the KISS1 precursor protein was separately named metastin, reflecting its original anti-metastatic research context, and the whole family of peptides derived from the same gene, of varying lengths, are collectively called kisspeptins.
Because of its central role upstream of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release, synthetic kisspeptin-54 has moved into early-phase human trials, mainly as a tool to study and potentially treat fertility issues, and separately as an experimental probe for effects on mood and anxiety. No kisspeptin-based drug has reached approval yet, and its current status is squarely research and early clinical development, not an available medicine.
Mechanism (plain language)
Stimulates hypothalamic GnRH neurons, driving downstream release of LH, FSH, and (in men) testosterone. This upstream mechanism differs fundamentally from melanocortin agonists like bremelanotide or Melanotan II.
How it works
Kisspeptin-54 works by stimulating specialized neurons in the hypothalamus that release gonadotropin-releasing hormone, or GnRH. GnRH is the hormone that in turn tells the pituitary gland to release LH and FSH, the two hormones that drive ovulation in women, sperm production in men, and testosterone and estrogen production in both sexes. In effect, kisspeptin sits one level upstream of GnRH, acting as a key gatekeeper that determines whether that whole downstream cascade fires.
This mechanism is distinct from other sexual-health-related peptides like bremelanotide or Melanotan II, which act on melanocortin receptors involved in desire and arousal circuits rather than on the reproductive hormone cascade itself. Controlled human infusion and injection studies in both men and women have reliably shown that kisspeptin-54 produces dose-dependent increases in LH and FSH. In women, the size of that response varies meaningfully depending on where they are in their menstrual cycle, with the strongest response seen during the preovulatory phase, which lines up with kisspeptin's proposed role in triggering the LH surge that causes ovulation.
What research suggests
Controlled human infusion and injection studies in both men and women reliably show dose-dependent increases in LH and FSH, with the female response varying by menstrual-cycle phase. It's being explored for fertility treatment (oocyte maturation triggers) and, separately, was tested for effects on anxiety with no significant effect found.
Reported benefits
What studies, case reports, and the research literature describe, not guaranteed outcomes. The trials behind these findings are in the studies below.
Reliable stimulation of reproductive hormones
Controlled human studies consistently report dose-dependent increases in LH and FSH after kisspeptin-54 administration in both men and women.
Testosterone increases in men
Intravenous infusion studies report significant increases in LH, FSH, and testosterone in healthy male volunteers.
Fertility treatment potential
Kisspeptin-54 is being explored as a trigger for oocyte maturation in assisted reproduction settings, an area of active clinical research.
Menstrual cycle-sensitive signaling
Research shows the hormonal response to kisspeptin varies predictably with cycle phase, offering insight into how the reproductive axis is regulated across the cycle.
Uncertainties & risks
Most human work is short-term physiology/pharmacology studies (infusions, single doses), not outcome trials on fertility or libido; no approved kisspeptin product exists yet. Animal studies on anxiety-related effects have been inconsistent, and a rigorous human RCT found no effect on anxiety measures.
Almost all human research on kisspeptin-54 to date consists of short-term physiology and pharmacology studies, single infusions or a small series of doses measuring hormone levels over hours, rather than outcome trials measuring whether it actually improves fertility, libido, or any other real-world endpoint over time. That is an important distinction: showing that a peptide reliably raises LH and FSH is not the same as showing it helps someone conceive or resolves a sexual-health complaint, and those longer trials largely have not been done yet. Kisspeptin has also been explored outside reproduction, particularly for effects on anxiety, an idea partly rooted in animal studies with inconsistent results. When this was tested rigorously in a human randomized controlled trial, kisspeptin-54 was found to have no significant effect on anxiety measures, a useful reminder that animal findings for kisspeptins do not automatically translate to people. No kisspeptin-based product has been approved by any regulatory agency, and its current place is in fertility-related and physiological research rather than as an accessible therapy.
STACKD study summaries
Start with our in-house roundups, plain-language synthesis of the research, with primary sources cited at the bottom of each.
Primary sources
Secondary citations for verification. Prefer the STACKD summary above for context before opening these.